INTERNATIONAL CONSORTIUM for INNOVATION & QUALITY in PHARMACEUTICAL DEVELOPMENT

REGISTRATION TO OPEN IN LATE JAN. 2026
IN PERSON ONLY

SAVE THE DATE!

IQ Workshop - Bioanalysis of Antibody-Drug Conjugates (ADCs)

MARCH 13, 2026

SPRING HOUSE INNOVATION PARK
SPRING HOUSE, PA

iqconsortium.org

PURPOSE

Save the date to join us for a full-day IQ Consortium workshop focused on harmonizing and streamlining bioanalytical practices for Antibody-Drug Conjugates (ADCs), reducing unnecessary complexity and resource use while maintaining scientific rigor and patient safety.

BACKGROUND

Bioanalysis of ADCs is uniquely challenging, requiring multiple assays (e.g., total antibody, conjugated antibody, free payload, metabolites, immunogenicity) across preclinical and clinical phases. Current industry practice often “measures everything,” resulting in high costs, excessive time demands, and large sample volumes. The IQ Consortium’s Drug Conjugates Working Group, co-chaired by Faye Vazvaei-Smith (Merck & Co. Inc.) and Wenkui Li (Novartis) is driving consensus on best practices to make ADC bioanalysis more efficient and fit-for-purpose.

GOAL

Develop clear consensus recommendations on which ADC constituent(s) should be measured—and when—enabling efficient fit-for-purpose bioanalysis across the stages of drug development. This includes alignment on:

- Which analyte(s)/assessment (e.g., total antibody, conjugated antibody, free payload, conjugated payload/metabolites/immunogenicity) are essential at each phase (preclinical, Phase I, pivotal studies, post-approval).
- When there is scientifical justification to start or stop measuring specific constituents.
- How to balance regulatory expectations with operational efficiency.

WORKSKHOP HIGHLIGHTS

- Plenary: The impact of bioanalysis on ADC development
- IQ Survey results: Current practices and opportunities for streamlining
- FDA participation (invited): Regulatory experience
- Breakout sessions: Practical guidance for “what to measure, when”
- Consensus-building: Drafting the IQ playbook for ADC bioanalysis

Who Should Attend?

- Bioanalytical, PK, and modeling scientists
- Clinical pharmacology professionals
- Regulatory affairs professionals
- Program strategists and operational leads

Why Attend?

- **Shape industry best practices** for ADC bioanalysis
- **Collaborate with leading experts** from IQ TALG, CPLG, Statistics LGs, and regulatory agencies (FDA invited)
- **Contribute to a decision framework** that reduces unnecessary complexity and resource use
- **Engage in breakout sessions** on assay strategy, PK/ER modeling, immunogenicity, and operational streamlining